VRTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.20%

Insider Buying (Last 12 Months): $1,948,400.00

Insider Selling (Last 12 Months): $111,755,773.65

Vertex Pharmaceuticals Insider Trading History Chart

Vertex Pharmaceuticals Share Price & Price History

^$418.16

▼ -11.692 (-2.72%)

As of 05/5/2026 01:12 PM ET

Days: 30 | 90 | 365

Vertex Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/1/2026	Joy Liu	EVP	Sell	978	$449.17	$439,288.26	21,833
3/13/2026	Carmen Bozic	CMO	Sell	2,329	$481.79	$1,122,088.91	35,405
2/25/2026	Amit Sachdev	EVP	Sell	1,846	$486.35	$897,802.10	55,570
2/25/2026	Duncan McKechnie	EVP	Sell	4,910	$487.65	$2,394,361.50	17,559
2/25/2026	E. Morrey Atkinson, III	EVP	Sell	668	$486.35	$324,881.80	18,432
2/25/2026	Jonathan Biller	EVP	Sell	945	$486.35	$459,600.75	13,659
2/25/2026	Kristen Ambrose	CAO	Sell	223	$486.35	$108,456.05	6,981
2/25/2026	Mark E. Bunnage	EVP	Sell	620	$486.35	$301,537.00	7,284
2/25/2026	Ourania Tatsis	EVP	Sell	260	$486.35	$126,451.00	46,763
2/19/2026	Amit Sachdev	EVP	Sell	58,613	$468.83	$27,479,532.79	58,934
2/13/2026	Ourania Tatsis	EVP	Sell	1,500	$499.99	$749,985.00	46,132
2/11/2026	E. Morrey Atkinson, III	EVP	Sell	1,751	$460.43	$806,212.93	22,046
2/11/2026	Jonathan Biller	EVP	Sell	1,925	$460.43	$886,327.75	20,819
2/11/2026	Kristen Ambrose	CAO	Sell	1,376	$460.43	$633,551.68	10,127
2/11/2026	Mark E. Bunnage	EVP	Sell	2,021	$460.43	$930,529.03	12,914
2/11/2026	Ourania Tatsis	EVP	Sell	466	$460.43	$214,560.38	51,436
1/7/2026	Ourania Tatsis	EVP	Sell	4,500	$474.99	$2,137,455.00	42,293
1/6/2026	Charles F. Wagner, Jr.	EVP	Sell	9,532	$461.00	$4,394,252.00	37,725
12/3/2025	Charles F. Wagner, Jr.	EVP	Sell	14,000	$456.00	$6,384,000.00	37,725
12/3/2025	Jeffrey M. Leiden	Chairman	Sell	63,781	$449.20	$28,650,425.20	24,026
11/14/2025	Jeffrey M. Leiden	Chairman	Sell	53,604	$440.72	$23,624,354.88	24,026
11/13/2025	Jeffrey M. Leiden	Chairman	Sell	19,688	$440.27	$8,668,035.76	24,026
8/6/2025	Bruce I. Sachs	Director	Buy	5,000	$389.68	$1,948,400.00	45,000
5/15/2025	David Altshuler	EVP	Sell	52	$424.69	$22,083.88	23,281
3/10/2025	David Altshuler	EVP	Sell	3,231	$500.00	$1,615,500.00	26,512
2/27/2025	Ourania Tatsis	EVP	Sell	530	$475.34	$251,930.20	58,539
2/18/2025	Ourania Tatsis	EVP	Sell	244	$455.06	$111,034.64	67,695
2/11/2025	Ourania Tatsis	EVP	Sell	310	$459.83	$142,547.30	64,021
11/15/2024	David Altshuler	EVP	Sell	15	$478.56	$7,178.40	25,813
8/30/2024	Jeffrey M. Leiden	Chairman	Sell	3,784	$499.00	$1,888,216.00	9,994
8/30/2024	Sangeeta N Bhatia	Director	Sell	646	$500.00	$323,000.00	4,435
8/7/2024	Carmen Bozic	CMO	Sell	2,280	$476.75	$1,086,990.00	23,259
8/1/2024	Bruce I. Sachs	Director	Sell	5,295	$508.00	$2,689,860.00	40,000
7/24/2024	Carmen Bozic	CMO	Sell	2,280	$488.46	$1,113,688.80	25,539
7/22/2024	Reshma Kewalramani	CEO	Sell	15,202	$497.00	$7,555,394.00	106,172
7/10/2024	Carmen Bozic	CMO	Sell	2,280	$487.34	$1,111,135.20	27,819
6/26/2024	Carmen Bozic	CMO	Sell	2,280	$471.72	$1,075,521.60	30,099
6/12/2024	Carmen Bozic	CMO	Sell	2,280	$478.00	$1,089,840.00	32,379
6/12/2024	E. Morrey Atkinson, III	EVP	Sell	7,288	$478.00	$3,483,664.00	15,972
5/30/2024	Ourania Tatsis	EVP	Sell	2,350	$439.11	$1,031,908.50	53,523
5/29/2024	Carmen Bozic	CMO	Sell	2,280	$445.56	$1,015,876.80	34,659
5/28/2024	Charles F. Wagner, Jr.	CFO	Sell	3,250	$454.79	$1,478,067.50	50,387
5/24/2024	Reshma Kewalramani	CEO	Sell	1,565	$457.00	$715,205.00	121,374
5/22/2024	Bruce I. Sachs	Director	Sell	7,073	$448.00	$3,168,704.00	40,000
2/26/2024	Ourania Tatsis	EVP	Sell	354	$425.70	$150,697.80	55,804
2/20/2024	Ourania Tatsis	EVP	Sell	480	$420.79	$201,979.20	59,827
2/12/2024	Amit Sachdev	EVP	Sell	3,222	$420.24	$1,354,013.28	74,364
2/12/2024	Jeffrey M. Leiden	Chairman	Sell	2,656	$419.51	$1,114,218.56	27,644
2/12/2024	Kristen Ambrose	CAO	Sell	1,374	$420.24	$577,409.76	9,676
2/12/2024	Stuart A. Arbuckle	COO	Sell	4,295	$420.24	$1,804,930.80	75,718
1/8/2024	Jeffrey M. Leiden	Chairman	Sell	6,648	$419.07	$2,785,977.36	2,423
11/6/2023	Bruce I. Sachs	Director	Sell	11,250	$385.00	$4,331,250.00	40,000
10/31/2023	Carmen Bozic	CMO	Sell	5,651	$355.92	$2,011,303.92	34,952
10/17/2023	Carmen Bozic	CMO	Sell	5,651	$373.25	$2,109,235.75	40,603
10/17/2023	Sangeeta N Bhatia	Director	Sell	243	$375.00	$91,125.00	3,901
10/16/2023	Jeffrey M. Leiden	Chairman	Sell	12,962	$374.00	$4,847,788.00	22,425
10/6/2023	Sangeeta N Bhatia	Director	Sell	242	$360.00	$87,120.00	4,144
10/3/2023	Carmen Bozic	CMO	Sell	5,651	$345.28	$1,951,177.28	46,254
10/2/2023	Jonathan Biller	EVP	Sell	610	$346.76	$211,523.60	10,569
9/19/2023	Carmen Bozic	CMO	Sell	5,651	$351.00	$1,983,501.00	51,905
8/23/2023	Ourania Tatsis	EVP	Sell	2,500	$355.00	$887,500.00	48,637
8/9/2023	David Altshuler	EVP	Sell	63	$345.51	$21,767.13	32,038
8/9/2023	Sangeeta N Bhatia	Director	Sell	242	$345.51	$83,613.42	4,386
7/17/2023	Bruce I. Sachs	Director	Sell	11,250	$356.75	$4,013,437.50	40,000
7/17/2023	Reshma Kewalramani	CEO	Sell	7,828	$355.00	$2,778,940.00	118,906
6/15/2023	Stuart A. Arbuckle	COO	Sell	8,603	$349.00	$3,002,447.00	56,556
5/30/2023	Kristen Ambrose	CAO	Sell	289	$329.82	$95,317.98	6,838
5/30/2023	Stuart A. Arbuckle	COO	Sell	82	$329.82	$27,045.24	56,556
5/8/2023	Bastiano Sanna	EVP	Sell	2,850	$350.00	$997,500.00	32,038
5/8/2023	Jeffrey M. Leiden	Chairman	Sell	1,125	$349.00	$392,625.00	35,387
5/5/2023	Bastiano Sanna	EVP	Sell	422	$350.03	$147,712.66	34,888
5/5/2023	Jeffrey M. Leiden	Chairman	Sell	879	$349.56	$307,263.24	36,512

SEC Filings (Institutional Ownership Changes) for Vertex Pharmaceuticals (NASDAQ:VRTX)

90.96% of Vertex Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Vertex Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/5/2026	Harel Insurance Investments & Financial Services Ltd.	3,014	$1.35M	0.0%	+23.7%	0.001%
5/5/2026	MASTERINVEST Kapitalanlage GmbH	8,293	$3.70M	0.4%	+49.6%	0.003%
5/5/2026	Sanctuary Advisors LLC	49,360	$22.04M	0.1%	-0.9%	0.019%
5/5/2026	Sigma Planning Corp	1,062	$0.47M	0.0%	-37.0%	0.000%
5/5/2026	Camden National Bank	20,907	$9.34M	1.3%	-0.3%	0.008%
5/5/2026	Checchi Capital Advisers LLC	1,570	$0.70M	0.0%	+13.4%	0.001%
5/5/2026	Roberts Glore & Co. Inc. IL	3,406	$1.52M	0.4%	-7.7%	0.001%
5/5/2026	Nwam LLC	6,332	$2.83M	0.2%	+25.7%	0.002%
5/5/2026	Hartford Funds Management Co LLC	3,101	$1.39M	0.1%	+0.9%	0.001%
5/4/2026	ABC Arbitrage SA	1,215	$0.54M	0.1%	N/A	0.000%
5/4/2026	Calamos Wealth Management LLC	1,834	$0.82M	0.0%	+183.0%	0.001%
5/4/2026	Calamos Advisors LLC	77,886	$34.78M	0.1%	+77.1%	0.031%
5/4/2026	Retirement Planning Group LLC	1,003	$0.45M	0.0%	+113.4%	0.000%
5/4/2026	Mattern Capital Management LLC	3,877	$1.73M	0.2%	+5.1%	0.002%
5/4/2026	Legacy Capital Group California Inc.	2,180	$0.97M	0.4%	-12.9%	0.001%
5/4/2026	Empirical Financial Services LLC d.b.a. Empirical Wealth Management	659	$0.29M	0.0%	-64.0%	0.000%
5/4/2026	Bleakley Financial Group LLC	17,226	$7.69M	0.1%	+10.5%	0.007%
5/4/2026	Illumine Investment Management LLC	5,782	$2.58M	2.0%	-0.7%	0.002%
5/4/2026	State of Michigan Retirement System	69,123	$30.87M	0.2%	-0.1%	0.027%
5/4/2026	Principal Financial Group Inc.	426,523	$190.46M	0.1%	+2.8%	0.168%
5/4/2026	Chicago Partners Investment Group LLC	1,170	$0.51M	0.0%	+34.9%	0.000%
5/4/2026	AMF Tjanstepension AB	312,917	$139.73M	0.9%	+114.4%	0.123%
5/4/2026	J. Safra Sarasin Holding AG	4,195	$1.87M	0.0%	+39.8%	0.002%
5/4/2026	Lifeworks Advisors LLC	3,022	$1.35M	0.2%	+3.4%	0.001%
5/4/2026	Teachers Retirement System of The State of Kentucky	36,725	$16.40M	0.1%	-8.9%	0.014%
5/2/2026	LGT Fund Management Co Ltd.	5,063	$2.26M	0.1%	N/A	0.002%
5/2/2026	Global Assets Advisory LLC	1,780	$0.80M	0.2%	+5.1%	0.001%
5/2/2026	Trifecta Capital Advisors LLC	16,757	$7.48M	1.2%	+1.6%	0.007%
5/2/2026	Anchor Investment Management LLC	391	$0.18M	0.0%	-21.0%	0.000%
5/2/2026	Associated Banc Corp	6,815	$3.04M	0.1%	-1.9%	0.003%
5/2/2026	UNIVEST FINANCIAL Corp	7,063	$3.15M	0.2%	+15.8%	0.003%
5/1/2026	Welch & Forbes LLC	219,669	$98.09M	1.3%	+0.7%	0.086%
5/1/2026	Commonwealth of Pennsylvania Public School Empls Retrmt SYS	59,167	$26.42M	0.1%	+0.3%	0.023%
5/1/2026	Cullinan Associates Inc.	51,762	$23.11M	1.9%	+0.9%	0.020%
5/1/2026	Citizens Financial Group Inc. RI	49,824	$22.25M	0.3%	+14.8%	0.020%
5/1/2026	Fifth Third Bancorp	88,499	$39.52M	0.1%	+299.4%	0.035%
5/1/2026	Sovran Advisors LLC	1,392	$0.60M	0.0%	+67.1%	0.001%
5/1/2026	Torray Investment Partners LLC	15,386	$6.87M	1.0%	-0.5%	0.006%
5/1/2026	Simplicity Wealth LLC	2,821	$1.26M	0.1%	+16.7%	0.001%
5/1/2026	Candriam S.C.A.	228,915	$102.22M	0.5%	+1.6%	0.090%
5/1/2026	Conning Inc.	1,167	$0.52M	0.0%	-16.6%	0.000%
5/1/2026	Sequoia Financial Advisors LLC	14,898	$6.65M	0.0%	+9.6%	0.006%
5/1/2026	Relyea Zuckerberg Hanson LLC	827	$0.37M	0.0%	+43.6%	0.000%
5/1/2026	Fulcrum Capital LLC	16,496	$7.37M	1.6%	-0.7%	0.006%
5/1/2026	Kornitzer Capital Management Inc. KS	2,210	$0.99M	0.0%	-1.6%	0.001%
5/1/2026	Manning & Napier Advisors LLC	220,589	$98.50M	1.4%	-48.4%	0.087%
4/30/2026	Equitable Trust Co.	562	$0.25M	0.0%	+13.3%	0.000%
4/30/2026	Whipplewood Advisors LLC	217	$97K	0.1%	+3,000.0%	0.000%
4/30/2026	Waterfront Wealth Inc.	2,169	$0.97M	0.2%	+4.2%	0.001%
4/30/2026	First Horizon Corp	14,535	$6.49M	0.3%	+19.6%	0.006%
4/30/2026	Cherry Creek Investment Advisors Inc.	1,332	$0.60M	0.3%	-4.9%	0.001%
4/30/2026	Kestra Advisory Services LLC	13,950	$6.23M	0.0%	-3.3%	0.005%
4/30/2026	Sumitomo Mitsui Trust Group Inc.	614,448	$274.38M	0.2%	-6.1%	0.242%
4/30/2026	Resona Asset Management Co. Ltd.	90,312	$40.28M	0.2%	+1.0%	0.036%
4/30/2026	Mitsubishi UFJ Morgan Stanley Securities Co. Ltd.	413	$0.18M	0.5%	-9.0%	0.000%
4/30/2026	Munich Reinsurance Co Stock Corp in Munich	260	$0.12M	0.0%	N/A	0.000%
4/30/2026	Personal CFO Solutions LLC	1,555	$0.69M	0.1%	+15.7%	0.001%
4/30/2026	Greenwood Capital Associates LLC	12,101	$5.40M	0.6%	-1.8%	0.005%
4/30/2026	Oregon Public Employees Retirement Fund	29,083	$12.99M	0.2%	+0.1%	0.011%
4/30/2026	Sageworth Trust Co	481	$0.22M	0.0%	N/A	0.000%
4/30/2026	Frank Rimerman Advisors LLC	3,317	$1.48M	0.1%	+1.1%	0.001%
4/30/2026	Quantum Portfolio Management LLC	801	$0.36M	0.0%	+45.6%	0.000%
4/30/2026	Stenger Family Office LLC	7,900	$3.53M	0.6%	+7.9%	0.003%
4/29/2026	Childress Capital Advisors LLC	608	$0.27M	0.0%	-16.7%	0.000%
4/29/2026	Koa Wealth Management LLC	2,468	$1.10M	0.8%	-4.5%	0.001%
4/29/2026	Resonant Capital Advisors LLC	1,776	$0.79M	0.0%	+13.4%	0.001%
4/29/2026	United Asset Strategies Inc.	2,965	$1.32M	0.1%	-1.5%	0.001%
4/29/2026	Burney Co.	4,810	$2.15M	0.1%	-12.0%	0.002%
4/29/2026	Swedbank AB	271,553	$121.26M	0.1%	+4.1%	0.107%
4/29/2026	Integrated Advisors Network LLC	1,481	$0.66M	0.0%	-31.9%	0.001%
4/29/2026	Baxter Bros Inc.	1,433	$0.64M	0.1%	-2.1%	0.001%
4/28/2026	PUREfi Wealth LLC	1,153	$0.52M	0.3%	+41.1%	0.000%
4/28/2026	Collaborative Fund Advisors LLC	930	$0.42M	0.3%	N/A	0.000%
4/28/2026	Kathmere Capital Management LLC	489	$0.22M	0.0%	N/A	0.000%
4/28/2026	Abel Hall LLC	1,474	$0.66M	0.1%	+8.4%	0.001%
4/28/2026	Whittier Trust Co.	1,830	$0.80M	0.0%	-7.3%	0.001%
4/28/2026	DGS Capital Management LLC	1,310	$0.59M	0.1%	+12.8%	0.001%
4/28/2026	Ascentis Independent Advisors	161	$72K	0.0%	N/A	0.000%
4/28/2026	Stephens Inc. AR	2,951	$1.32M	0.0%	-4.6%	0.001%
4/28/2026	GM Advisory Group LLC	502	$0.22M	0.0%	-4.7%	0.000%
4/28/2026	Walkner Condon Financial Advisors LLC	578	$0.26M	0.0%	N/A	0.000%
4/28/2026	Howe & Rusling Inc.	9,721	$4.34M	0.3%	+2.1%	0.004%
4/28/2026	Private Wealth Partners LLC	1,385	$0.62M	0.0%	+12.1%	0.001%
4/28/2026	Koshinski Asset Management Inc.	1,608	$0.72M	0.0%	+10.4%	0.001%
4/28/2026	V Square Quantitative Management LLC	5,706	$2.55M	0.3%	+1.5%	0.002%
4/28/2026	Beacon Financial Advisory LLC	569	$0.25M	0.1%	+5.0%	0.000%
4/28/2026	QRG Capital Management Inc.	19,900	$8.89M	0.1%	+8.2%	0.008%
4/27/2026	Simplify Asset Management Inc.	7,936	$3.54M	0.1%	-54.6%	0.003%
4/27/2026	HB Wealth Management LLC	10,287	$4.59M	0.0%	+8.6%	0.004%
4/27/2026	BIP Wealth LLC	1,307	$0.58M	0.0%	+7.6%	0.001%
4/27/2026	Baer Investment Advisory LLC	517	$0.23M	0.0%	N/A	0.000%
4/27/2026	World Investment Advisors	1,820	$0.81M	0.0%	-7.7%	0.001%
4/27/2026	Turtle Creek Wealth Advisors LLC	938	$0.42M	0.0%	+29.7%	0.000%
4/27/2026	New York State Teachers Retirement System	211,336	$94.37M	0.2%	+0.1%	0.083%
4/27/2026	Private Advisor Group LLC	8,433	$3.77M	0.0%	-3.0%	0.003%
4/27/2026	Optas LLC	1,160	$0.52M	0.1%	+12.1%	0.000%
4/27/2026	Y Intercept Hong Kong Ltd	35,829	$16M	0.3%	N/A	0.014%
4/27/2026	Leonteq Securities AG	4,260	$1.90M	0.1%	-15.2%	0.002%
4/27/2026	Fjarde AP Fonden Fourth Swedish National Pension Fund	149,962	$66.96M	0.4%	+68.4%	0.059%
4/27/2026	New World Advisors LLC	515	$0.23M	0.0%	N/A	0.000%

Data available starting January 2016

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $418.16

$412.27

$433.94

50 Day Range

MA: $453.82

$423.24

$499.17

52 Week Range

Now: $418.16

$362.50

$507.92

Volume

1,008,039 shs

Average Volume

1,389,459 shs

Market Capitalization

$106.36 billion

P/E Ratio

27.28

Dividend Yield

N/A

Beta

0.3

Who are the company insiders with the largest holdings of Vertex Pharmaceuticals?: Vertex Pharmaceuticals' top insider shareholders include:
Jeffrey M Leiden (CEO)
Joshua S Boger (Director)
Joshua Boger (Director)
Joshua S Boger (Director)
Jeffrey M Leiden (CEO)
Jeffrey Leiden (CEO)
Peter Mueller (EVP)
Ian F Smith (CFO)
Stuart A Arbuckle (EVP)
Jeffrey Chodakewitz (CMO)
Learn More about top insider investors at Vertex Pharmaceuticals.
Who are the major institutional investors of Vertex Pharmaceuticals?: Vertex Pharmaceuticals' top institutional investors include:
Sumitomo Mitsui Trust Group Inc. — 0.24%
Assenagon Asset Management S.A. — 0.21%
Principal Financial Group Inc. — 0.17%
Pictet Asset Management Holding SA — 0.13%
AMF Tjanstepension AB — 0.12%
Swedbank AB — 0.11%
Learn More about top institutional investors of Vertex Pharmaceuticals stock.
Which major investors are selling Vertex Pharmaceuticals stock?: Within the previous quarter, VRTX stock was sold by these institutional investors:
Pictet Asset Management Holding SA
Assenagon Asset Management S.A.
Manning & Napier Advisors LLC
SG Americas Securities LLC
Sumitomo Mitsui Trust Group Inc.
ABN AMRO Bank N.V.
Generate Investment Management Ltd
Simplify Asset Management Inc.
In the last year, company insiders that have sold Vertex Pharmaceuticals company stock include:
Amit Sachdev (EVP)
Ourania Tatsis (EVP)
Charles F Wagner Jr (EVP)
Carmen Bozic (CMO)
Jeffrey M Leiden (Chairman)
David Altshuler (EVP)
Edward Morrow Atkinson III (EVP)
Joy Liu (EVP)
Jonathan Biller (EVP)
Duncan Mckechnie (EVP)
Mark E Bunnage (EVP)
Kristen Ambrose (CAO)
Learn More investors selling Vertex Pharmaceuticals stock.
Which major investors are buying Vertex Pharmaceuticals stock?: During the previous quarter, VRTX stock was acquired by institutional investors including:
AMF Tjanstepension AB
Fifth Third Bancorp
Fjarde AP Fonden Fourth Swedish National Pension Fund
BI Asset Management Fondsmaeglerselskab A S
Y Intercept Hong Kong Ltd
Calamos Advisors LLC
Louisiana State Employees Retirement System
OP Asset Management Ltd